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Abstract
Background:  Excess  body  mass  increases  the  risk  of  development  of  asthmatic  symptoms  and
their severity  and  decreases  the  treatment  effectiveness.  One  of  the  hypotheses  explaining
the link  between  the  two  diseases  concerns  the  adipokines,  hormones  produced  by  adipose
tissue with  a  proinflammatory  character.  The  aim  of  this  study  was  to  compare  the  levels  of
the adipokines  (leptin  and  resistin)  between  overweight  asthmatic  patients,  asthmatic  patients
with normal  weight  and  overweight  patients  without  asthma.
Methods:  80  peripheral  blood  samples  were  collected  from  patients  and  blood  serum  extracted.
Three groups  were  selected:  overweight  asthmatic  patients  (BMI  ≥  25),  overweight  patients
without asthma  and  asthmatic  patients  with  normal  weight  (BMI  <  25).  Waist  circumference  of
the patients  was  measured  (cut-off  points  were  80  cm  for  women  and  over  94  cm  for  men)  and
a skin  prick  test  performed.  Comparison  of  adipokine  concentration  between  the  3  groups  was
made and  association  between  these  concentrations  and  the  measurements  was  performed.
Results: Although  the  concentrations  of  both  adipokines  were  slightly  higher  for  overweight
asthmatic patients  compared  to  overweight  healthy  patients,  these  differences  were  not  signif-
icant. A  significant  association  was  found  between  leptin  concentration  and  both  BMI  (p  <  0.01)
and waist  circumference  (p  <  0.01).  A  difference  for  this  cytokine  was  also  found  between
asthmatic  and  non-asthmatic  female  patients  (p  <  0.05).
Conclusions:  As  expected  overweight  patients  with  BMI  ≥  25  and  patients  with  increased  waist
circumference  showed  higher  leptin  levels.  We  suggest  that  the  studied  cytokines,  with  a
loaded from http://zl.elsevier.es, day 20/10/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.stronger  indication  for  leptin,  can  elicit  asthmatic  inflammation  in  obese  phenotype  of  asthma
that affects  more  frequently  women.
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s  defined  by  the  World  Health  Organization  (WHO)  asthma
s  a  chronic  inflammatory  airways  disease  characterized  by
ecurrent  attacks  of  wheezing  and  breathlessness.1 Asthma
nflammation  involves  the  recruitment  of  various  cells  and
ellular  elements  such  as  immunoglobulins  and  cytokines
hat  will  result  in  airways  mechanical  and  physiological
hanges.  Asthmatic  patients  have  narrowed  airways  due  to
he  bronchi  edema  and  thickening  achieved  by  the  hyper-
rophy  and  hyperplasia  of  the  smooth  muscle  cells  (result
f  the  VEGF  --  vascular  endothelial  growth  factor  secre-
ion)  and  their  contraction.  Additional  airflow  problems  are
aused  by  the  increased  secretion  of  mucus.2
Obesity  and  overweight  is  ‘‘abnormal  or  excessive  fat
ccumulation  that  may  impair  health’’.3 In  the  last  decades
he  prevalence  of  asthma  and  obesity  increased  signifi-
antly  in  industrialized  countries  becoming  a  burden  not
nly  for  affected  patients  but  also  public  health  systems.4,5
his  convergence  captured  the  interest  of  researchers  and
esulted  in  various  studies  examining  the  link  between  the
wo  conditions.  It  soon  became  clear  that  obesity  is  a  strong
isk  factor  for  asthma  development,  affecting  prevalence,
everity  and  treatment  effectiveness  in  obese  patients.6
Body  mass  index  (BMI)  measured  in  kg  per  square  meter  is
he  most  commonly  parameter  used  to  assess  the  excess  of
eight  and  obesity.  Numerous  epidemiological  studies  found
 significant  association  between  BMI  and  asthma  symptoms
oth  in  adults7,8 and  children.9 However,  contrary  results  can
lso  be  found.10,11 BMI,  despite  being  the  most  frequent,  is
ot  the  most  precise  measure  of  the  fat  excess.  This  index
escribes  only  the  relation  of  the  total  body  mass  to  height,
ot  taking  into  consideration  the  actual  proportion  of  the
at  versus  lean  mass  or  the  fat  distribution.
Another  commonly  used  indicator  for  obesity,  examining
he  fat  distribution,  is  the  waist  circumference.  Central  obe-
ity  (fat  concentration  around  the  waist  area)  is  a  strong  risk
actor  for  cardiovascular  diseases  and  type  2  diabetes.12 A
tudy  run  in  the  Hunter  Medical  Research  Institute,  New  Cas-
le,  Australia,  considered  in  obesity-related  asthma  studies
ot  only  BMI  but  also  body  composition  and  waist  circumfer-
nce.  A  significant  association  was  encountered  indicating
 detrimental  impact  of  increased  fat  mass  and  both  tho-
acic  and  android  fat  tissue  on  respiratory  health  (expiratory
eserve  volume  --  ERV)  in  women.  In  men  the  association  was
ound  with  thoracic  and  android  lean  issue  and  ERV.  How-
ver,  leptin  concentration,  also  included  in  this  analysis,  was
ositively  associated  with  thoracic  and  android  fat  tissue  in
en.13
Several  studies  indicate  that  obesity-related  asthma  phe-
otype  is  observed  more  commonly  in  women.  Von  Behren
t  al.  used  not  only  BMI  but  also  waist  size  in  the  cohort  study
f  88,304  women  and  found  a  positive  association  between
hese  measurements  and  current  asthma,  with  waist  cir-
umference  being  independently  associated  with  asthma
ymptoms,  even  in  the  group  of  women  with  normal  BMI
tatus.14
Various  hypotheses  were  presented  trying  to  explain
he  mechanism  causing  the  association.  One  explanation
ocuses  on  the  common  environmental  factors  for  both  dis-
ases,  namely  sedentary  lifestyle  and  changes  in  diet.  Other
ypotheses  implicate  the  reduced  lung  capacity  caused  by
c
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he  mechanical  impact  of  body  mass  on  the  chest,  gastro-
sophageal  reflux  and  sleep-disordered  breathing.15 Recent
tudies  have  shown  that  adipose  tissue  has  not  only  a  pas-
ive  energy  storage  role  but  is  also  physiologically  active
aving  endocrine  functions.  Hormones  secreted  by  this  tis-
ue  are  called  adipokines  and  their  main  role  is  to  regulate
unger  and  satiety,  although  they  are  also  involved  in  inflam-
ation  processes.  The  most  indicated  adipokines  suggested
o  have  an  impact  on  asthma  development  are  leptin  and
esistin.16 Leptin  is  a  16  kDa  protein  of  167  amino  acids  is
 product  of  ob  gene  (gene  of  obesity)  in  humans.  Food
ntake  results  in  the  increased  expression  of  this  gene  and
s  a  consequence,  of  leptin  serum  concentration.  The  leptin
eceptor  gene  (db)  is  expressed  in  the  lung  tissue.  The  pres-
nce  of  the  receptors  itself  indicates  the  lungs  as  the  target
rgan  for  this  hormone.17 Resistin  is  a  recently  discovered
2.5  kDa  adipokine  belonging  to  a  cysteine-rich  secretory
rotein  family.  Resistin  is  expressed  in  human  macrophages,
one  marrow,  spleen,  mononuclear  leucocytes  and  at  low
evels  in  adipose  tissue.  This  hormone  concentrates  around
he  inflamed  tissue,  up-grading  its  own  expression  and
romoting  the  NF-B  activation  and  cytokine  production
pso  facto  triggering  the  inflammation.  Similarly  to  lep-
in,  resistin  levels  increase  with  increased  adipose  mass.18
oth  hormones  described  above  are  important  mediators
f  the  metabolic  processes  with  pro-inflammatory  charac-
er.  Higher  serum  concentrations  of  both  adipokines  were
bserved  in  asthmatic  patients  with  an  even  stronger  asso-
iation  for  women.19
ethods
uestionnaire  data  collection
he  database  and  sample  used  in  this  work  is  a  part  of  a
arger  project  making  part  of  the  Global  Allergy  and  Asthma
uropean  Network  (GA2LEN).20 Data  collection  was  carried
ut  in  2010  and  centered  on  the  population-based  sam-
le  of  2200  individuals  aged  between  18  and  74  years  old.
s  recommended  by  the  GAL2EN  protocol,  the  sample  was
elected  randomly.  A  short  questionnaire  including  ques-
ions  about  birth  date,  gender  and  asthma  symptoms  was
anded  to  the  participants  to  be  filled  in  and  returned  by
ail.  Three  attempts  were  undertaken  in  order  to  obtain
he  best  response  rate.  A  skin  prick  test  was  conducted  on
he  randomly  selected  sub-sample  of  asthmatics.  The  pres-
nce  of  asthma  symptoms  was  determined  using  the  GINA
lassification.21
nthropometric  measurements
ll  the  individuals  participating  in  the  study  were  measured
nd  weighed  (with  light  clothing  and  barefoot).  BMI  was
alculated  with  the  formula
MI  = weight  (kg)
height  (m) ×  height  (m)Using  the  cut-off  points  recommended  by  the  WHO  we
onsidered  individuals  with  a  BMI  value  equal  to  or  greater
han  25  as  overweight  and  equal  to  or  greater  than  30  as
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obese,  but  due  to  the  small  sample  of  obese  patients,  we
included  the  obese  individuals  in  overweight  group  and  used
it  as  one  for  all  the  analyses.
Waist  circumference  was  measured  using  the  measuring
tape,  and,  as  recommended  by  the  WHO,  cut-off  points  of
80  cm  and  94  cm  were  used  for  women  and  men,  respec-
tively.
Final  sample  selection
Individuals  born  before  1945  were  excluded  from  the  study,
as  they  are  already  classified  as  elderly  and  could  express
hormonal  changes  related  to  the  aging  process  rather  than
fat  tissue  excess  or  asthmatic  inflammation.  Three  groups
were  selected  in  order  to  perform  the  adipokine  concentra-
tion  comparison.  Overweight  (including  obese)  patients  with
asthma  (28  individuals)  and  overweight  without  asthma  (26
individuals)  were  selected  in  order  to  measure  the  impact
of  asthma  on  adipokines  serum  concentrations.  The  third,
the  control  group,  consisted  of  asthmatic  patients  with  BMI
values  within  normal  range  (26  individuals).
Adipokine  concentration  measurements
The  blood  serum  of  the  80  selected  individuals  was  analyzed
to  measure  the  leptin  and  resistin  serum  concentration  using
ELISA  kits.  As  the  dilution  proportions  were  suggested  in  the
protocol,  after  a  bibliographic  research  and  optimization
protocol  for  several  dilutions  we  chose  to  use  1:20  dilu-
tion  for  leptin  and  left  the  resistin  undiluted.  The  minimum
detectable  concentration  was  0.016  ng/ml  for  resistin  and
0.313  ng/ml  for  leptin.
Statistical  analyses
The  Software  PASW  Statistics  v18  and  Numbers  ‘09  was
used  for  the  data  processing  and  statistical  analysis.  Val-
ues  of  p  <  0.05  were  considered  as  statistically  significant.
To  compare  the  concentrations  between  selected  groups,
Kruskal--Wallis  and  Mann--Whitney  U  test  were  used  as  the
data  did  not  have  a  normal  distribution  (KS  <  0.05).  Values
for  women  were  calculated  separately  due  to  the  hypothe-
ses  of  phenotype  of  obesity-related  asthma  having  a  stronger
association  with  the  female  gender.
Results
For  the  purposes  of  the  investigation  three  groups  were
selected:
Group  1:  28  asthmatic  individuals  with  BMI  ≥  25  kg/m2
(mean  BMI  =  30.4  ±  4.3);  assigned  as  overweight  with
asthma  (including  14  obese  patients  with  BMI  >  30).
Group  2:  26  non-asthmatic  individuals  with  BMI  ≥  25  kg/m2
(mean  BMI  =  28.9  ±  4.2);  assigned  as  overweight  without
asthma  (including  9  obese  patients  with  BMI  >  30).
Group  3:  26  asthmatic  individuals  with  BMI  <  25  kg/m2
(mean  BMI  =  21.6  ±  1.9);  assigned  as  normal  weight  with
asthma.
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Women  had  significantly  higher  serum  levels  of  lep-
in  compared  to  men.  Serum  concentrations  of  resistin  in
omen  also  occurred  higher  but  the  difference  was  not  sig-
ificant  (Table  1).
When  we  analyzed  all  population  considering  only  BMI  or
aist  circumference,  as  expected,  the  group  of  people  with
MI  ≥  25  kg/m2 and  the  group  with  waist  circumference  val-
es  above  recommended  (over  80  cm  for  women  and  over
4  cm  for  men),  had  significantly  higher  levels  of  serum  lep-
in  (Table  1) and  these  differences  were  even  stronger  for
omen  population  (Table  2).
No  association  was  found  between  hormone  levels  and
llergy  presence,  but  on  dividing  allergic  patients  into  sub-
roups  of  mono-  and  poly-sensitised,  a  significant  difference
as  observed  between  the  mono-sensitised  and  the  other
wo  groups  (no  allergy,  poly-sensitised)  in  leptin  concentra-
ion  (Table  1).
As  we  can  see  in  Table  3  and  Fig  1,  when  compar-
ng  the  three  groups  of  overweight  patients  with  asthma
group  1),  overweight  patients  without  asthma  (group  2)
nd  individuals  with  normal  weight  and  asthma  (group  3),
ithout  division  between  sexes,  a  significant  difference  in
erum  leptin  levels  was  found.  However,  as  shown  in  Fig.  1,
he  results  turned  non-significant  when  comparing  only  the
wo  groups  of  overweight  patients  with  and  without  asthma.
fter  the  division  between  sexes,  significant  differences
ould  be  found  also  only  between  the  groups  1 and  2,  and
roups  2  and  3.  No  significant  difference  between  asthmatic
nd  healthy  overweight  patients  was  observed.
In  case  of  resistin,  for  all  the  variables  included,  no  signif-
cant  associations  were  found  neither  in  the  total  population
or  within  genders.
iscussion
dipokines  are  the  proteins  secreted  by  the  adipose  tissue
nvolved  in  the  regulation  of  the  energy  balance  with  the
ecently  suggested  putative  role  in  allergic  inflammation
ncreasing  the  risk  of  asthma  in  obese  individuals.15 The
ssociation  between  adipokine  concentration  and  asthma
as  been  discovered  to  be  even  stronger  in  women.19 In  our
tudies  we  analyzed  two  cytokines:  leptin  and  resistin.  As
xpected,  patients  with  excess  weight  expressed  a  signif-
cantly  increased  level  of  leptin  in  serum.  The  difference
as  significant  both  for  individuals  with  BMI  equal  to  or  over
5  and  for  those  with  waist  circumference  over  80  cm  for
omen  and  94  cm  for  men.  A  significantly  increased  level
f  adipokines  in  women  as  well  as  a  stronger  association
etween  their  concentrations  and  obesity  resulted  in  cre-
ting  a  separate  phenotype  of  obesity-related  asthma  that
redominantly  affects  this  sex.  The  difference  in  fat  distri-
ution  between  men  and  women  is  widely  known.  In  women
e  can  more  frequently  observe  the  physiological  fat  accu-
ulation  in  the  hip  area  (pear  shape/gynoid  pattern)  while
n  men  the  abdominal  area  is  the  main  storage  part  (apple
hape/android  pattern).  However,  this  is  not  the  only  differ-
nce.  Recent  studies  suggest  that  the  difference  is  in  fact
ot  found  in  physiological  fat,  present  in  the  adipose  tis-
ue,  but  in  so-called  ectopic  fat.  This  fat  is  present  in  the
iscera  or  muscles.  Although  men  tend  to  have  more  vis-
eral  fat,  it  is  more  active  in  women.  Muscular  fat  as  well
418  M.  Muc  et  al.
Table  1  Comparison  of  leptin  and  resistin  serum  concentrations  within  selected  variables  for  total  studied  population.  Non-
parametric tests,  Kruskal--Wallis  and  Mann--Whitney,  were  used  to  compare  the  concentrations  between  groups  and  the  p  ≤  0.05
was considered  significant  (*)  and  p  ≤  0.01  strongly  significant  (**).
Total  population
Variable  Resistin  Leptin
n  Mean
(±SD)
(ng/ml)
Median  p-Value  n  Mean
(±SD)
(ng/ml)
Median  p-Value
Sex
Feminine  43  0.715
(±0.059)
0.734 0.340 49  82.17
(±46.82)
77.59 0.000**
Masculine 23  0.702
(±0.059)
0.709  30  38.12
(±32.16)
26.75
Body mass  index
BMI  <  25 21  0.695
(±0.066)
0.690  0.290  26  39.66
(±28.31)
34.56  0.010**
BMI ≥  25 45  0.718
(±0.053)
0.732 53  78.09
(±49.13)
74.66
Waist circumference
Recommended  36  0.704
(±0.065)
0.708  0.510  41  51.41
(±39.61)
37.26  0.007**
Above recommended  30  0.718
(±0.050)
0.731  38  80.59
(±49.80)
75.28
Allergy
No allergy  27  0.704
(±0.063)
0.700  0.790  30  57.97
(±41.40)
45.07  0.030*
Mono-sensitised  9  0.724
(±0.045)
0.734  11  103.28
(±50.91)
107.15
Poly-sensitised  28  0.711 0.725  36  62.06 54.74
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s  physiological  fat  levels  are  higher  for  the  female  sex.
n  muscles,  due  to  its  visual  aspect  it  is  often  said  to  cre-
te  a  ‘‘marbling’’  effect  on  the  muscle  tissue.  The  protein
nvolved  in  the  marbling  of  the  muscle  is  leptin.19 These  dif-
erences  could  be  the  underlying  reason  for  the  increased
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igure  1  Comparison  of  the  leptin  (A)  and  resistin  (B)  concentratio
ignificance of  the  differences  between  each  pair  of  compared  grou(±46.22)
dipokine  concentrations  in  women,  that  we  also  establish
n  our  study.
When  comparing  the  mean  values  of  leptin  concentra-
ions  between  the  three  studied  groups  (overweight  with
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ns  between  the  three  studied  groups  for  men  and  women.  The
ps  is  presented  with  the  p  values  under  the  lines.
Leptin  and  resistin  in  overweight  patients  419
Table  2  Comparison  of  leptin  and  resistin  serum  concentrations  within  selected  variables  considering  only  women.  Non-
parametric tests,  Kruskal--Wallis  and  Mann--Whitney,  were  used  to  compare  the  concentrations  between  groups  and  the  p  ≤  0.05
was considered  significant  (*)  and  p  ≤  0.01  strongly  significant  (**).
Women
Variable  Resistin  Leptin
n  Mean
(±SD)
(ng/ml)
Median  p-Value  n  Mean
(±SD)
(ng/ml)
Median  p-Value
Body  mass  index
BMI  <  25 17  0.695
(±0.060)
0.690  0.074  21  45.10
(±28.76)
37.26  0.000**
BMI ≥  25 26  0.728
(±0.055)
0.745 28  109.97
(±37.60)
109.84
Waist Circum.
Recommended  24  0.703
(±0.064)
0.701  0.203  28  62.73
(±38.25)
55.29  0.001**
Above recommended  19  0.730
(±0.049)
0.740  21  108.09
(±45.28)
110.63
Allergy
No allergy  16  0.707
(±0.063)
0.706  0.815  18  78.73
(±39.46)
91.62  0.117
Mono-sensitised  8  0.732
(±0.041)
0.735  8  115.49
(±50.06)
129.62
Poly-sensitised  19  0.714
(±0.062)
0.740  23  73.27
(±47.81)
58.32
Table  3  Comparison  of  the  leptin  and  resistin  serum  concentrations  between  the  three  studied  groups.  Non-parametric  test,
Kruskal--Wallis,  was  used  to  compare  the  concentrations  between  the  groups.  The  p  ≤  0.05  was  considered  significant  (*)  and
p ≤  0.01  strongly  significant  (**).
Adipokine  Groups  Total  population  Women
n  Mean
(±SD)
(ng/ml)
Median  p-Value  n  Mean
(±SD)
(ng/ml)
Median  p-Value
Leptin Group  1
BMI  ≥  25
With  asthma
28  78.12
(±44.65)
76.45  0.006*  17  106.66
(±29.74)
102.77  0.000*
Group 2
BMI  ≥  25
Without  asthma
25  78.06
(±54.65)
73.39  11  115.09
(±48.52)
121.76
Group  3
BMI  <  25
With  asthma
26  39.66
(±28.31)
34.56  21  45.10
(±28.76)
37.26
Total  79  49
Resistin Group 1
BMI  ≥  25
With  asthma
23  0.720
(±0.057)
0.746  0.456  15  0.734
(±0.053)
0.757  0.160
Group 2
BMI  ≥  25
Without  asthma
22  0.715
(±0.051)
0.727  11  0.720
(±0.059)
0.734
Group  3
BMI  <  25
With  asthma
21  0.695
(±0.067)
0.690  17  0.695
(±0.060)
0.690
Total  66  43
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ith  asthma)  we  can  observe  a  significant  difference  (even
tronger  in  women)  which,  however,  is  not  evident  when
liminating  the  normal  weight  group  (Fig.  1).  This  suggests
hat  the  main  factor  determining  the  difference  in  leptin
oncentration  is  the  excess  of  fat  rather  than  presence  of
sthma.  Similarly,  no  difference  in  leptin  concentrations
as  also  reported  in  a  Korean  study  in  children  although
t  did  show  the  negative  correlations  of  this  protein  with
ulmonary  functions  such  as  forced  respiratory  volume  in
 second  and  flow  respiratory  volume  between  25  and  75%.
n  the  same  study  significant  concentration  differences  were
ound  for  resistin  which  was  not  the  case  in  our  work.22
s  suggested  in  the  article  published  by  Sood  et  al.,  lep-
in  levels  might  not  be  the  link  in  the  association  between
he  obesity  and  asthma.  Although  in  this  work  a  significant
ssociation  was  found  between  BMI  and  leptin  levels  as  well
s  the  leptin  levels  and  asthma  in  women,  the  associations
urned  out  to  be  independent  and  the  research  did  not  con-
rm  that  leptin  is  in  fact  the  link  between  the  two  diseases.23
his  could  also  be  the  reason  why  in  our  study,  the  concen-
rations  of  leptin  were  significantly  associated  with  BMI,  but
o  difference  was  observed  when  comparing  the  asthmatic
verweight  group  with  the  healthy  overweight  group.  The
ack  of  association  could  also  be  due  to  the  fact  of  the  BMI
eing  a  very  general  index  for  risks  related  to  obesity,  as
t  excludes  influence  of  the  fat  distribution  and  type.  BMI
oes  not  discriminate  visceral  nor  intramuscular  fat  propor-
ions,  which  seem  to  have  much  stronger  association  with
he  elevated  risk  of  morbidities  than  physiological  fat.
Not  only  asthma,  but  also  an  atopy  was  described  to
e  linked  with  increased  body  mass.  A  positive  correla-
ion  between  levels  of  IgE  and  leptin  was  observed  in
topic  patients  and  obesity  is  considered  a  risk  factor  for
llergies.24 In  our  population,  allergic  individuals  had  an
ncreased  level  of  both  leptin  and  resistin  but  the  differ-
nce  was  not  significant.  Interestingly,  significantly  higher
evels  were  expressed  in  poly-sensitised  patients  compared
o  mono-sensitised  and  non-allergic  patients.
onclusions
ummarizing,  the  results  of  the  presented  work  indi-
ate  a  modification  in  the  systemic  levels  of  leptin,  a
rotein  produced  predominantly  by  adipocytes,  in  over-
eight  (including  obese)  patients  with  the  association  being
tronger  for  women.  No  significant  difference  was  found
etween  the  group  of  overweight  asthmatics  and  over-
eight  non-asthmatic  patients.  Our  study  suggests  that  the
bserved  differences  in  concentrations,  especially  for  lep-
in,  can  strengthen  the  inflammatory  response  of  airways
nd  contribute  to  the  severity  of  asthma  in  obese  individ-
als,  but  in  the  future  research,  apart  from  the  physiological
at  tissue,  role  visceral  and  intramuscular  fat  should  be
ncluded  in  the  analysis.
revious presentation of resultsart  of  the  results  has  been  previously  presented  in  the  form
f  posters  (EAACI  Summit  on  Asthma  Severity  and  Exacer-
ations,  2nd  PF2MUC  Symposium  --  Changing  Paradigms  of
cience  Faculty  of  Medicine  of  University  of  Coimbra),  andM.  Muc  et  al.
ral  presentation  with  abstract  (International  Conference
‘Advances  in  Pneumology’’,  in  Conference  Proceedings
ttp://pneumology.pl/index.php?id=program, Wroclaw).
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   Para tratamiento preestacional o perenne
1. DENOMINACIÓN DEL MEDICAMENTO: ALLERGOVAC POLIMERIZADO y ALLERGOVAC POLIMERIZADO 1 DÍA. 2. COMPOSICIÓN: Extractos alergénicos estandarizados biológicamente en unidades TPU/ml, polimerizados con glutaraldehído, purificados 
por ultrafiltración y analizados por técnicas inmunoquímicas. Se presentan suspendidos en solución salina fisiológica fenolada. 3. FORMA FARMACÉUTICA: Suspensión estéril para inyección por vía subcutánea. 4. DATOS CLÍNICOS: 4.1 Indicaciones 
terapéuticas: Enfermedades alérgicas respiratorias mediadas por IgE y causadas por alérgenos, que cursan con rinitis, rinoconjuntivitis y asma bronquial. 4.2 Posología y forma de administración: ALLERGOVAC POLIMERIZADO: La presentación 
consta de cuatro viales (numerados como 0, 1, 2 y 3) para utilizar en la fase de iniciación del tratamiento. El esquema de administración de la iniciación consiste en una administración semanal de una única dosis de 0,5 ml de cada vial, comenzando por 
el 0 y hasta llegar al 3. Una semana después de finalizado este tratamiento de iniciación, se comienza con el de continuación, que consta de uno o dos viales 3, del que se tomarán las dosis de mantenimiento, a razón de 0,5 ml con intervalo mensual. 
Las inyecciones subcutáneas deben realizarse en la cara exterior dorsal del brazo, en la línea media entre el hombro y el codo, alternando de brazo cada vez. ALLERGOVAC POLIMERIZADO 1 DÍA: La presentación consta de dos viales 3 con los que se 
realizan las fases de iniciación y continuación del tratamiento. El esquema de administración de la iniciación consiste en dos administraciones en un único día, comenzando con una dosis de 0,2 ml y siguiendo, a los 30 minutos con otra de 0,3 ml. A los 
30 días comienza el tratamiento de mantenimiento, aplicando el volumen restante de los dos viales a razón de 0,5 ml con intervalo mensual. Las inyecciones subcutáneas deben realizarse en la cara exterior dorsal del brazo, en la línea media entre el 
hombro y el codo, alternando de brazo cada vez. 4.3 Contraindicaciones: Trastornos del sistema inmunitario o neoplasias; asma severo incontrolable; enfermedades renales, hepáticas o hematológicas; tuberculosis activa; fiebre superior a los 38,5ºC; 
enfermedades en las que el uso de adrenalina esté contraindicado, como enfermedades coronarias o hipertensión arterial severa; tratamiento simultáneo con bloqueadores beta-adrenérgicos. No se debe desarrollar cualquier actividad física intensa tras 
la administración de una dosis. 4.4 Advertencias y precauciones de empleo: ALLERGOVAC POLIMERIZADO y ALLERGOVAC POLIMERIZADO 1 DÍA sólo deben aplicarse si se dispone de medios inmediatamente accesibles, que permitan proceder al 
tratamiento de un paciente que eventualmente sufra una reacción generalizada (urticaria, asma, shock anafiláctico, etc.), tales como adrenalina por vía intramuscular u otros. Por eso estos tratamientos deben administrarse en centros convenientemente 
dotados. No deben ser administrados en ningún caso en el domicilio del paciente. Después de la aplicación de cada una de las dosis, el paciente permanecerá 30 minutos como mínimo en el centro donde se le haya administrado el preparado. Ante la 
aparición de cualquier reacción adversa, antes de proseguir con el tratamiento, consultar con el médico prescriptor. 4.5 Interacción con otros medicamentos y otras formas de interacción: La tolerancia del paciente a la inmunoterapia puede 
estar aumentada transitoriamente por el uso de medicamentos antialérgicos (antihistamínicos, corticoides, etc.), por tanto si la administración de éstos se interrumpe debe valorarse la posibilidad de reducir la dosis de ALLERGOVAC POLIMERIZADO y 
ALLERGOVAC POLIMERIZADO 1 DÍA en previsión de eventuales reacciones adversas. 4.6 Embarazo y lactancia: No se debe iniciar la administración de la inmunoterapia con vacunas alergénicas durante el embarazo. Si el embarazo se produce cuando 
el tratamiento ha llegado a la dosis de mantenimiento, no habiéndose presentado reacciones adversas de importancia, podrá continuarse. 4.7 Efectos sobre la capacidad de conducir y utilizar máquinas: No tiene efectos conocidos a este respecto. 
4.8 Reacciones adversas: Aunque poco frecuente en este tipo de tratamiento modificado, se pueden presentar reacciones locales, consistentes en enrojecimiento, prurito  e induración en el lugar de la inyección que son normales, siempre y cuando 
no excedan del tamaño de 5 cm de diámetro. Así mismo, pueden surgir reacciones sistémicas, que consisten en la aparición de síntomas producidos por la inmunoterapia fuera del lugar de inyección, incluyendo: rinitis, urticaria, angioedema, asma y 
anafilaxia pudiendo aparecer entre 15 minutos y 4-6 horas después de la inyección subcutánea. Las reacciones locales grandes (superiores a 5-10 cm de diámetro) pueden requerir la aplicación de frío local y/o antihistamínicos orales. Las sistémicas 
pueden precisar la administración de adrenalina, antihistamínicos, corticosteroides, fluidoterapia y broncodilatadores (en caso de broncospasmo). Si la reacción sistémica es tardía, el paciente debe informar a su médico o acudir al servicio médico más 
cercano. 4.9 Sobredosis: En caso de una sobredosis accidental o de una aplicación incorrecta del tratamiento, pueden presentarse cuadros de reacciones adversas como los descritos en el apartado 4.8. 5. PROPIEDADES FARMACOLÓGICAS: 5.1 
Propiedades farmacodinámicas: Grupo farmacoterapéutico: Alérgenos. Código ATC:V01A. 5.2 Propiedades farmacocinéticas: Se trata de una preparación en la que los alérgenos están en suspensión acuosa formando polímeros con lo que se 
reduce su capacidad de unión de IgE tras su liberación en el punto de inyección. 6. DATOS FARMACÉUTICOS: 6.1 Lista de excipientes: Fenol, cloruro sódico, agua calidad inyectable. 6.2 Incompatibilidades: Ninguna. 6.3 Periodo de validez: No 
utilizar ALLERGOVAC POLIMERIZADO y ALLERGOVAC POLIMERIZADO 1 DIA después de la fecha de caducidad indicada en la etiqueta. 6.4 Precauciones especiales de conservación: Conservar entre 2ºC y 8ºC (en nevera). No congelar. 6.5 Naturaleza 
y contenido del recipiente: ALLERGOVAC POLIMERIZADO: La suspensión se presenta en cuatro viales de vidrio tipo I, numerados del 0 al 3, con concentraciones crecientes y con un volumen útil de 1,0 ml cada uno, en la presentación de iniciación. Por 
su parte, la continuación presenta 1 ó 2 viales de vidrio tipo I, identificados con el número 3, a máxima concentración y con un volumen útil de 2,4 ml de suspensión. ALLERGOVAC POLIMERIZADO 1 DÍA: La suspensión se presenta en dos viales de vidrio 
tipo I, identificados con el número 3 y con un volumen útil de 2,4 ml de suspensión cada uno. 6.6 Instrucciones de uso y manipulación: Previamente a la extracción de la dosis que corresponda administrar, el vial debe ser agitado suavemente. Deben 
emplearse jeringas tipo tuberculina de 1 ml graduadas en décimas de ml. Las agujas deben ser subcutáneas, de un calibre aproximado de 4 décimas de mm. Siendo un preparado multidosis, deben extremarse las precauciones para asegurar la esterilidad 
de las dosis siguientes. 7. CONDICIONES DE PRESCRIPCIÓN Y DISPENSACIÓN: Con receta médica. Financiable por la Seguridad Social. 8. NOMBRE DEL TITULAR: Bial Industrial Farmacéutica S.A., Parque Científico y Tecnológico de Bizkaia, Edif 401, 
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